Table 1.
Sociodemographic characteristics and clinical and laboratory data of patients with sickle cell anemia and healthy individuals (control group).
| AA (n = 50) | SS (n = 47) | SSHU (n = 54) | p-Value* | |
|---|---|---|---|---|
| Sex: Male/Female | 28/22 | 22/25 | 23/31 | – |
| Age (years) | 34.6 (18; 55) | 32 (18; 69) | 32.17 (19; 63) | – |
| Erythrocytes (×1012/L) | 4.5 (4.2; 5.2) | 2.66 (1.77; 4.0) | 2.61 (1.73; 3.82) | 0.724 |
| Hemoglobin (g/dL) | 13.5(12.2; 15.2) | 8.20 (5.57; 11.53) | 9.21 (5.5; 12.4) | 0.001 |
| Hematocrit (%) | 41 (37; 49) | 24.05 (16.9; 32.9) | 26.40 (17.6; 34.3) | 0.005 |
| MCV (fL) | 87 (79; 92.1) | 90.8 (74.4; 107.6) | 101.8 (79.7; 134.4) | <0.001 |
| MCH (pg) | 28.9 (25.9; 31.6) | 30.9 (24.4; 37.7) | 35.5 (27.3; 47.8) | <0.001 |
| Leukocytes (×109/L) | 5.1 (4.2; 8.4) | 12.29 (5.55; 22.10) | 9.83 (3.20; 19.70) | 0.002 |
| Neutrophils (%) | 47 (39; 51) | 59 (41; 85) | 49 (31; 72) | 0.048 |
| Reticulocytes (×103/µL) | NA | 272.5 (110.9; 597.8) | 235.4 (110.5; 433.3) | 0.518 |
| Platelets (×106/µL) | 220 (148; 312) | 371 (154; 798) | 388.2 (385; 880.4) | 0.904 |
| HbF (%) | NA | 5.6 (0.6; 13.8) | 15.12 (1.9; 38.7) | <0.001 |
AA: Control group (healthy individuals); SS: SCA patients not taking hydroxyurea; SSHU: SCA patients on hydroxyurea therapy; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; HbF: fetal hemoglobin; NA: not available. Data presented (except for M/F) as means (minimum; maximum). (*) p-value obtained using the Kruskal–Wallis test.